Gsk Share Discussion Threads

[ny boy] 21/2/2017 17:30

Well it's going up on this leg, 1715p will be difficult to get through, so could retrace to around 1645p imho but I don't really sell at resistance, just hold and add more on any retrace.

[bracke] 21/2/2017 17:21

Toffee

Gold star for you. maurillac missed 'sideways'.

Worth keeping an eye on the price action if you are thinking of a, I'll say it quietly, short.

[toffeeman] 21/2/2017 16:49

Nah it may go up or down or sideways :)

[maurillac] 21/2/2017 15:07

so it could go up or down, or up, down and up again ;)
m

[bracke] 21/2/2017 12:46

Having reached the Median Line (middle green) it's decision time. Best option is 'zoom' through and keep going. Second best is move above ML then drop back for a successful retest. Third best is as second best but test fails to hold. Equal third, fails to break above ML and simply retraces.

I suppose I should mention the possibility that the share price simply tracks up along the ML.

GSK DAILY

[minerve] 21/2/2017 12:19

Courtesy of Rowan Dartington:

GlaxoSmithKline (GSK.L) Buy Income Risk 3
The Pharmaceuticals company recently announced Final results to December 2016. The results were in line with expectations with Group sales rising +17% to £27.9bn (+5% constant exchange rates), aided by a weak Sterling and growth in new products. In terms of outlook, 2017 Group EPS will depend on the timing and degree of the impact of US generic competition on Glaxo's asthma drug, Advair. Assuming a bearish case for Advair (assumes US Advair sales fall -45% to $1.36bn in 2017), core EPS will be flattish if competition begins mid-year Valuing the Group on a Dec’17 P/E of 14.5x, an 11% discount to the Market. This is good value considering that the Pharmaceutical division should not be impacted significantly by generics for several years post 2017. Total Pharmaceutical sales should be slightly higher in 2020 compared to 2016 due to new products (+£2.2bn to £6bn by 2020) outweighing the decline in US Advair sales (c £1.3bn in total). The two other divisions, Vaccines and Consumer Healthcare, should continue to trade well on the back of the Novartis acquisitions. The Group is trading at a discount to its Global Consumer Healthcare peers who trade on an average P/E of around 20x. The yield of 5% should also offer great protec-tion in these uncertain equity markets. Trump should not impact the pharmaceutical sector too much because competition has worked well in terms of the patent rules and of the strength of the Pharmacy Benefit Managers.

[ny boy] 21/2/2017 09:00

Onwards to 1715p resistance, within a rising trend channel

[ny boy] 20/2/2017 00:00

No, what is it, buy/sell?

[somptinglad] 17/2/2017 21:18

Hi there, did anybody notice the 1,351,062 trade at 16.39

[ny boy] 17/2/2017 17:59

With the £ heading lower, who knows, it's possible, it's just one of a few that have been earmarked before, the low £ allows a pedestrian to make a blow out offer, therefore likely to meet approval of shareholders..interesting times ahead.

[spoole5] 17/2/2017 17:40

Unilever today, will glaxo be next...?

[ny boy] 17/2/2017 09:47

Figures, also defensive qualities when the markets correct.

Sterling’s collapse makes GlaxoSmithKline plc an attractive takeover target

[philanderer] 17/2/2017 09:44

17th feb Jefferies buy tp 1800p up from 1780p

[ny boy] 17/2/2017 07:55

Tks, I must if been thinking of another stock.

[garycook] 17/2/2017 07:41

XD,Next Thursday 23th Feb 23p per share.Paid on Thursday 13th of April.

[ny boy] 17/2/2017 07:38

Isn't it ex div today?

[tim 3] 16/2/2017 15:40

flying today.

Next stop £17, or maybe a pause at 16.50?

[ny boy] 16/2/2017 12:18

Breaking higher

[losos] 16/2/2017 11:46

NY Boy - Seems to be doing well, I'm happy with the ViiV statement, good start for new CEO, but things can change haha.

[ny boy] 16/2/2017 08:17

Broken through 1592p resistance, closes above this level, suggest a crack at next resistance level 1715p this quarter.

[ny boy] 16/2/2017 08:05

Breakout coming?

[philanderer] 15/2/2017 13:20

Beaufort Securities note:

Our view: Positive progress for ViiV Healthcare. The announcement follows positive headline results announced on 20 December 2016. The details study results are being presented at the annual Conference on Retroviruses and Opportunistic Infections in Seattle.

Although share price moved marginally adverse yesterday, possibly due to investors wished to see Virologic suppression rates for two-drug regimen superior against the CAR arms, the result itself came no surprise since the December.

The Group said for over 20 years, the industry believed that three or more drugs were required to maintain virologic suppression, but the study of dolutegravir and rilpivirine provide data showing suppression may be maintained with a two-drug regimen. The studies are ongoing for 148 weeks, and the Group is planning regulatory submissions for this two-drug regimen as a single tablet during 2017.

GSK was entitled to approximately 80% of the core earnings of ViiV Healthcare for 2016 (allocation of the overall earnings of ViiV Healthcare to each shareholder will change based on the relative performance of the products), meaning that, if progress continues along the same lines as in 2016, this should be slightly earnings enhancing for GSK going forward.

In light of the on-going developments, Beaufort maintain a Buy rating on GlaxoSmithKline with a target price of 1,750p per share.


proactiveinvestors.co.uk